Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N. Cranston A, et al. Among authors: ashworth a. Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z. Trials. 2017. PMID: 28270164 Free PMC article. Clinical Trial.
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho JS, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A. Rajan N, et al. Among authors: ashworth a. Oncogene. 2011 Oct 13;30(41):4243-60. doi: 10.1038/onc.2011.133. Epub 2011 May 9. Oncogene. 2011. PMID: 21552290 Free PMC article.
Inherited cylindromas: lessons from a rare tumour.
Rajan N, Ashworth A. Rajan N, et al. Among authors: ashworth a. Lancet Oncol. 2015 Sep;16(9):e460-e469. doi: 10.1016/S1470-2045(15)00245-4. Lancet Oncol. 2015. PMID: 26370355 Review.
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.
Rajan N, Andersson MK, Sinclair N, Fehr A, Hodgson K, Lord CJ, Kazakov DV, Vanecek T, Ashworth A, Stenman G. Rajan N, et al. Among authors: ashworth a. J Pathol. 2016 Jun;239(2):197-205. doi: 10.1002/path.4717. Epub 2016 Apr 21. J Pathol. 2016. PMID: 26969893 Free PMC article.
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N. Danilenko M, et al. Among authors: ashworth a. JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610. JAMA Dermatol. 2018. PMID: 29955768 Free PMC article. Clinical Trial.
BRCAness revisited.
Lord CJ, Ashworth A. Lord CJ, et al. Among authors: ashworth a. Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18. Nat Rev Cancer. 2016. PMID: 26775620 Review.
Marked for death: targeting epigenetic changes in cancer.
Pfister SX, Ashworth A. Pfister SX, et al. Among authors: ashworth a. Nat Rev Drug Discov. 2017 Apr;16(4):241-263. doi: 10.1038/nrd.2016.256. Epub 2017 Mar 10. Nat Rev Drug Discov. 2017. PMID: 28280262 Review.
845 results